Hedley Mary Lynne
SEC-identified person · CIK 1340823 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Centessa Pharmaceuticals plc CNTA | Director | filed 2021–2026 |
| Veeva Systems INC VEEV | Director | filed 2019–2026 |
| Lilly ELI & CO LLY | Director | filed 2022–2025 |
| Tempest Therapeutics, Inc. TPST | Director | filed 2018–2020 |
| Tesaro, Inc. TSRO | Director · President and COO | filed 2012–2019 |
| Bluebird bio, Inc. BLUE | Director | filed 2017–2018 |
| Receptos, Inc. RCPT | Director | filed 2014–2015 |
| New Abraxis, Inc. ABII | Executive VP of Ops & CSO | filed 2009–2009 |
| MGI Pharma INC MOGN | Sr. VP & Chief Scientific Off | filed 2006–2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.